WHO has the malaria vaccine, the strategy, and the surveillance network. What it does not have is the budget.

The Seventy-ninth World Health Assembly closed on Saturday 23 May 2026 with 13 resolutions adopted and 20-plus decisions recorded. The closing-day update lists confirmed adoptions on stroke, liver disease, tuberculosis, antimicrobial resistance, diagnostic imaging, emergency care, haemophilia, precision medicine, radiation, and the Global Action Plan on AMR (2026-2036). It does not list a single resolution on malaria, dengue, chikungunya, vector-borne disease, mosquito control, climate-and-health, RTS,S or R21 malaria vaccines, PMI/USAID funding, or Gavi. Agenda item A79/4 ("Recommitting to accelerate progress towards malaria elimination") stayed on the table all week and produced no fresh decision text. The vector-borne disease file did not make it to the top of the room.

This is the editorial story of the spring of 2026, and it lands inside the same fortnight as the most consequential malaria-vaccine result of the decade.

The vaccine works, and the proof is published

On 8 May 2026, The Lancet published the observational evaluation of the RTS,S/AS01E Malaria Vaccine Implementation Programme: across Ghana, Kenya, and Malawi over the four-year implementation window from 2019 to 2023, RTS,S averted approximately one in eight deaths from any cause among children eligible to receive it. WHO issued a same-day statement endorsing the result. WHO's own extrapolation, "the positive impact is likely to be as high or higher in other African countries now offering malaria vaccines to young children in areas of high malaria burden", was the most consequential sentence the agency has issued on malaria in the decade.

The Serum Institute of India is producing R21/Matrix-M at a target capacity of 200 million doses per year at US$3.90 per dose, and 25 African countries have already rolled out at least one malaria vaccine. The vaccine works. The supply is in place. The pipeline is full.

The wallet is empty

The 2025 funding number was US$3.9 billion. The 2025 target was US$9.3 billion. The shortfall projected by WHO and partners is now US$5.4 billion per year. The cascade is concrete and traceable:

• Mozambique recorded more than four times as many malaria cases in the first quarter of 2026 as in the same period of 2025.
• Namibia recorded 2.5 times the case-load of all of 2024 in the first quarter of 2026 alone.
• Nigeria recorded more than 24 million cases in nine months of 2025.
• Global Fund has cut US$1.4 billion from existing grants in response to recent US foreign-aid reductions, and the malaria programme is running an estimated 30 percent budget shortfall.
• PMI (the U.S. President's Malaria Initiative) is operating at roughly 47 percent of its 2024 budget.
• Gavi estimates 600,000 fewer lives will be saved by the end of the decade under the funding gap as it currently stands.

The cascade is now visible at the country level, in the ECDC and WHO surveillance data, and in the press coverage that has begun to use the phrase "malaria funding crisis" without qualification.

Why the WHA79 silence is the structural fact

A World Health Assembly resolution is the political mechanism a member state uses to commit to a budget line. No resolution means no budget line. The 13 resolutions WHA79 did adopt (tuberculosis, AMR, stroke, radiation, and so on) were each the product of multi-year member-state negotiation; their absence from the malaria file means that the 2026 budget cycle for malaria control will continue to run on the same disbursement architecture it ran on in 2025, with the same shortfalls. There is no Assembly-level decision in the pipeline that could close the US$5.4 billion gap before the 2027 disbursement cycle.

The structural sentence is now ready: the vaccine works, the supply is in place, the wallet to pay for the last mile is empty. Everything else is a footnote.

What the 2026 data tells us about the science behind the wallet

Pyrethroid resistance is now confirmed in 48 of 53 reporting African countries. Artemisinin partial resistance is documented in four African countries. Anopheles stephensi, the urban, container-breeding vector, has expanded through urban Africa and now threatens 126 million city-dwellers. India's official Malaria Elimination Technical Report 2025 formally flagged An. stephensi as the single biggest risk to India's 2030 elimination target; the mosquito already accounts for roughly 12 percent of Indian malaria cases. The 2026 challenge is therefore not a 2010s challenge of "we need a vaccine and a net and more money." It is a 2026 challenge of "the vaccine is here, the next-generation nets are here, the surveillance is here, but the resistance is here too, and the budget to deploy all three at the scale that closes the gap is not."

What to do

• For donor governments: the WHA79 silence is the cue. The Assembly is the annual moment when member states align political commitment with budget. Treat the 2027 cycle as the structural fix point; the 2026 disbursement cycle will not close the gap on its own.
• For national malaria programmes: prioritise the deployment of next-generation nets (Interceptor G2, PBO-synergist, dual-AI nets) in pyrethroid-resistance-confirmed areas. The discriminating-concentration guidance WHO published on 11 June is the operational reference for which nets to use where.
• For clinicians in returning-traveller settings: An. stephensi urban-establishment is the reason malaria should be in the differential for an unexplained fever in a returned traveller from any African or South-Asian city, not only from a rural setting.
• For consumer-protection messaging: the structural funding gap is the reason that home-front personal protection, skin-applied repellent, insecticide-treated bed nets, screened windows, treated clothing, is a permanent part of the answer, not an emergency supplement to it. The vector-control system is doing less, not more, in 2026.

Published 2026-05-24 · Mosticare Editorial